Meeting
2020 Genitourinary Cancers Symposium
Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
Authors
Howard I. Scher
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Howard I. Scher , Fred Saad , Maneesha Mehra , Sandhya Nair , Lindsay Dearden , Ravi C. Potluri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 92)
Abstract #
92
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf
First Author: Elena Castro